Predictive Inc., is a Pennsylvania corporation engaged in the research, development and marketing of medical devices and related services for early detection of infections. Predictive has proprietary technology, Biosymtec™, which can detect, noninvasively, respiratory and non-respiratory infections in monitored individuals up to two days before symptoms, such as a fever, permitting early, less expensive, medical intervention. Early detection and intervention shortens illnesses and drastically reduces the need for emergency room visits and hospitalizations. Medications given early, through early detection of infections, are more effective.
Infectious diseases such as influenza, pneumonia and bronchitis are serious threats to those with COPD, asthma and those with compromised immune systems. Each year in the United States asthma and COPD cause enormous human and economic costs. Over 25 million people, suffer from asthma. Asthma causes over 10 million office visits, two million ED visits, 500,000 hospitalizations, and over 3,000 deaths each year. Asthma costs the U.S. $56 Billion annually.
Almost 15 million people have been diagnosed with COPD, and the National Heart, Lung and Blood Institute (NHLBI) estimates at least another 12 million more additional cases go undiagnosed. It has been the third-leading cause of death in the US. Annual healthcare costs associated with COPD have reached $50 billion, including 739,000 hospitalizations and over 15 million office visits annually.
Biosymtec™ Detecting the presence of an infection before it has overwhelmed an individual's immune system, followed by early medical treatment, improves outcomes and reduces the cost of treatment by orders of magnitude. The threat of that person spreading the infection to other persons is also greatly reduced.